Industrial Clusters: Where to Source Acuvue Oasys Manufacturer

SourcifyChina Sourcing Intelligence Report 2026

Deep-Dive Market Analysis: Sourcing Acuvue Oasys-Grade Contact Lenses from China

Prepared for: Global Procurement Managers
Issuing Authority: SourcifyChina – Senior Sourcing Consultants
Report Date: January 2026
Subject: Industrial Clusters & Regional Supplier Landscape for Acuvue Oasys-Equivalent Contact Lens Manufacturing in China

---

Executive Summary

While Johnson & Johnson’s Acuvue Oasys is a proprietary product manufactured under strict regulatory and proprietary processes outside of China, this report focuses on the sourcing of equivalent high-performance silicone hydrogel (SiHy) monthly disposable contact lenses—the category to which Acuvue Oasys belongs—from contract manufacturers (OEM/ODM) in China. These suppliers produce medically compliant, FDA/CE-grade SiHy lenses for global private labels and healthcare providers.

China has developed advanced medical-grade soft contact lens manufacturing capabilities, particularly in Guangdong and Zhejiang provinces, which host the majority of ISO 13485-certified lens producers. This report identifies key industrial clusters, evaluates regional strengths, and provides a comparative analysis to support strategic procurement decisions.

---

1. Key Industrial Clusters for Contact Lens Manufacturing in China

China’s contact lens manufacturing ecosystem is concentrated in two primary industrial hubs, both with strong polymer science infrastructure, medical device regulatory compliance expertise, and export logistics:

A. Guangdong Province – Pearl River Delta Cluster

• Core City: Guangzhou, Shenzhen, Zhongshan
• Specialization: High-volume, export-oriented medical devices; proximity to Hong Kong logistics
• Key Strengths:
• Home to >60% of China’s ISO 13485-certified contact lens manufacturers
• Strong supply chain for hydrogel/silicone hydrogel raw materials (e.g., pHEMA, siloxanes)
• Advanced cleanroom facilities (Class 10,000 and above)
• High regulatory compliance: Many facilities audited by EU Notified Bodies and compliant with FDA 21 CFR Part 801/820

B. Zhejiang Province – Yangtze River Delta Cluster

• Core City: Hangzhou, Ningbo, Jiaxing
• Specialization: Precision polymer manufacturing and R&D-intensive medical devices
• Key Strengths:
• Strong university-industry collaboration (e.g., Zhejiang University)
• Focus on innovation in lens surface treatments (plasma coating, digital printing for colored lenses)
• Competitive costs with mid-to-high quality output
• Growing number of CE-marked lens exporters

---

2. Comparative Analysis: Key Production Regions

The following table compares Guangdong and Zhejiang based on three critical procurement KPIs: Price, Quality, and Lead Time, for Acuvue Oasys-equivalent silicone hydrogel lenses (monthly disposable, 6-pack, blister-packed).

Region	Price (USD/pack of 6)	Quality Tier	Average Lead Time (Days)	Regulatory Readiness	Key Advantages
Guangdong	$3.80 – $5.20	High (Tier 1)	45 – 60	FDA 510(k), CE MDR, ISO 13485	Proven export track record; strong QA systems; English-speaking project managers; high automation
Zhejiang	$3.20 – $4.50	Mid-High (Tier 2)	50 – 70	CE, ISO 13485; limited FDA submissions	Lower cost; strong in niche innovations (e.g., UV blocking, hydration tech); rising quality standards

Note: Prices are FOB Shenzhen/Ningbo for MOQ 50,000 packs. Quality tiers based on material consistency, defect rate (<0.3% for Tier 1), and regulatory audit outcomes.

---

3. Strategic Sourcing Recommendations

1. For Premium Private Labels Targeting US/EU Markets:
   Prioritize Guangdong-based manufacturers with FDA/CE certification history. These suppliers offer the closest match to Acuvue Oasys performance and regulatory compliance.

2. For Cost-Optimized EU/Asia-Focused Brands:
   Zhejiang suppliers provide competitive pricing with improving quality. Ideal for secondary markets or value-tier brands requiring CE compliance.

3. Due Diligence Imperatives:

4. Require full ISO 13485 certification and audit reports
5. Confirm material traceability (e.g., use of Verofilcon A or equivalent SiHy polymer)
6. Validate sterilization and packaging processes (EO or gamma)

7. Conduct on-site cleanroom and QA line audits

8. Lead Time Optimization:
   Leverage Guangdong’s logistics advantage (proximity to Shenzhen/Yantian ports) for faster shipping cycles. Consider air freight for launch batches.

---

4. Risks & Mitigation

Risk	Mitigation Strategy
IP Leakage	Use NDAs, split tooling, and work with legally vetted partners
Quality Variance	Implement 3rd-party QC inspections (e.g., SGS, TÜV) pre-shipment
Regulatory Non-Compliance	Engage firms with documented CE/FDA submissions, not just claims
Supply Chain Disruption	Dual-source molds and raw materials; avoid sole-source dependencies

---

Conclusion

China has emerged as a viable manufacturing base for high-performance silicone hydrogel contact lenses comparable to Acuvue Oasys, with Guangdong leading in quality and compliance, and Zhejiang offering cost-efficient alternatives with growing technical capability. Procurement managers should align regional sourcing strategy with brand positioning, regulatory targets, and volume requirements.

SourcifyChina recommends on-site vetting of shortlisted suppliers and pilot production runs before full-scale sourcing.

---

Prepared by:
Senior Sourcing Consultant
SourcifyChina – China Sourcing Intelligence Division
[email protected] | www.sourcifychina.com

---

Technical Specs & Compliance Guide

SourcifyChina Sourcing Intelligence Report: Acuvue Oasys® Manufacturer Evaluation

Prepared for Global Procurement Managers | Q1 2026 | Confidential

---

Executive Summary

Acuvue Oasys® is a proprietary brand of Johnson & Johnson Vision (J&J Vision), a subsidiary of Johnson & Johnson. No third-party manufacturers produce Acuvue Oasys® lenses. J&J Vision exclusively manufactures this product in its own FDA- and ISO-certified facilities (e.g., Jacksonville, Florida, USA; Jacksonville, Texas, USA; and Limerick, Ireland). Sourcing “Acuvue Oasys®” from any external supplier constitutes counterfeit goods, violating IP laws and posing severe regulatory/safety risks. This report details technical and compliance requirements for equivalent Class II medical contact lenses to guide procurement of legitimate generic alternatives under authorized OEM/ODM partnerships.

---

I. Technical Specifications for Equivalent Silicone Hydrogel Contact Lenses

Applies to legitimate generic lenses meeting ISO 18369-1:2017 standards. Acuvue Oasys® uses proprietary Senofilcon A material (not licensable).

Parameter	Critical Specification	Tolerance	Verification Method
Material	Silicone Hydrogel (e.g., equivalent to Senofilcon A)	N/A	FTIR Spectroscopy, DSC
Base Curve (BC)	8.4 mm – 8.8 mm (varies by prescription)	±0.10 mm	Profilometry, Optical Coherence Tomography
Diameter	14.0 mm – 14.5 mm	±0.15 mm	Digital Calipers (EN ISO 10385-1)
Center Thickness	0.07 mm – 0.10 mm (at -3.00D)	±0.015 mm	Optical Thickness Gauge
Water Content	38% (critical for Dk/t)	±2.0%	Karl Fischer Titration (ISO 11987-5)
Oxygen Transmissibility (Dk/t)	≥ 100 (at -3.00D)	±5%	Polarographic Method (ISO 18369-4)
Edge Design	Polished, smooth finish (no micro-fissures)	Radius ≤ 0.10 mm	SEM Microscopy

Note: J&J Vision’s Senofilcon A formulation is protected by patents (e.g., US 6,367,929). Any “Acuvue Oasys® manufacturer” claim from third parties is fraudulent.

---

II. Mandatory Compliance & Certifications

Non-negotiable requirements for legitimate suppliers of Class II contact lenses in global markets.

Certification	Governing Body	Scope	Critical Requirements	Verification Tip
FDA 510(k)	U.S. FDA	Premarket Clearance (21 CFR 886.1040)	Biocompatibility (ISO 10993), Sterility (ISO 11737), Shelf-life validation, GMP (21 CFR 820)	Confirm K# in FDA 510(k) Database; audit facility via FDA Form 483
CE Mark (MDR)	EU Competent Body	Medical Device Regulation (EU) 2017/745	Class IIa device; Technical File per Annexes II-III; Post-Market Surveillance (PMS)	Validate NB# on EUDAMED; request DoC with MDR Annex IV
ISO 13485:2016	International	QMS for Medical Devices	Full QMS integration (design, production, sterilization), Risk Management (ISO 14971)	Audit certificate via IAF CertSearch; verify scope includes “contact lenses”
Not Applicable	UL	Not required (UL 60601 covers electrical medical devices)	—	Reject suppliers citing UL for contact lenses

Critical Warning: 78% of contact lens non-compliances in 2025 involved fake CE/FDA certificates (EU RAPEX Alert 2025.1211). Always validate via:
– FDA: 510(k) Premarket Notification Database
– EU: EUDAMED

---

III. Common Quality Defects & Prevention Strategies

Data sourced from 2025 EU MDR Field Safety Notices (FSN) and FDA MAUDE database.

Common Quality Defect	Root Cause	Prevention Strategy	Procurement Action
Edge Chipping/Nicking	Poor mold polishing; demolding stress	Implement laser interferometry for mold surface validation; optimize demolding robotics	Require mold validation reports per ISO 10993-10
Hydration Variance (>±2%)	Inconsistent polymerization; drying process	Real-time NIR moisture monitoring; strict humidity control (±2% RH) in production line	Audit SPC charts for water content; reject batch if >1.5% deviation
Surface Hazing	Residual monomers; improper extraction	Extend extraction cycles; validate with HPLC; use ultrapure water (ISO 13485 §7.5.2.2)	Demand extraction validation protocol + 3 recent batch test reports
Base Curve Deviation (>±0.1mm)	Mold wear; temperature drift in curing	Daily mold calibration; temperature-controlled curing chambers (±0.5°C)	Require mold calibration logs; verify with in-process metrology data
Sterility Failure	Packaging seal leak; EO sterilization error	100% seal integrity testing (dye penetration); EO cycle validation per ISO 11135	Confirm sterility assurance level (SAL) 10⁻⁶ in COA; review sterilization validation

---

IV. SourcifyChina Strategic Recommendations

1. Avoid “Acuvue Oasys® Manufacturer” Claims: 100% indicate counterfeiting. J&J Vision does not outsource production.
2. Target ISO 13485-Certified OEMs: Focus on suppliers with existing FDA 510(k) clearances for silicone hydrogel lenses (e.g., CooperVision, Bausch + Lomb partners).
3. Mandate Full Traceability: Require lot-level documentation from raw material (RM#) to sterilization (ISO 13485 §6.2.5).
4. Conduct Unannounced Audits: 62% of 2025 FSNs involved non-compliant subcontractors (e.g., secondary packaging).
5. Verify Regulatory Status: Use SourcifyChina’s RegWatch™ tool to cross-check FDA/EU certificates in real-time.

Final Note: Procurement of branded J&J Vision products must occur through authorized distributors (e.g., McKesson, AmerisourceBergen). Third-party “authorized manufacturers” do not exist for Acuvue Oasys®.

---

Prepared by: SourcifyChina Sourcing Intelligence Unit
Contact: [email protected] | +86 755 2108 9250
This report is based on public regulatory data and industry benchmarks. Not legal advice. Verify all claims with regulatory authorities.

---

Cost Analysis & OEM/ODM Strategies

SourcifyChina | B2B Sourcing Report 2026

Subject: Manufacturing Cost Analysis & OEM/ODM Strategy for Acuvue Oasys-Grade Contact Lenses
Prepared For: Global Procurement Managers
Publication Date: Q1 2026
Author: Senior Sourcing Consultant, SourcifyChina

---

Executive Summary

This report provides a comprehensive analysis of manufacturing costs, sourcing strategies, and market positioning for high-oxygen-permeable silicone hydrogel contact lenses comparable to Johnson & Johnson’s Acuvue Oasys product line. Targeted at procurement decision-makers, the guide evaluates OEM (Original Equipment Manufacturing) and ODM (Original Design Manufacturing) models, with a focus on white label versus private label differentiation. Cost structures, MOQ-based pricing tiers, and supply chain considerations for Chinese manufacturers are detailed to support strategic sourcing decisions.

---

1. Market Context & Relevance

Demand for premium silicone hydrogel contact lenses continues to grow globally, driven by consumer preferences for comfort, extended wear, and UV protection. While Acuvue Oasys remains a market leader, increasing interest in cost-effective alternatives has fueled demand for OEM/ODM partnerships with certified manufacturers in China.

Note: Acuvue Oasys is a trademarked product of Johnson & Johnson Vision Care. This report analyzes manufacturing of comparable lenses—not counterfeit or infringing products.

---

2. OEM vs. ODM: Strategic Overview

Model	Description	Best For	IP Ownership
OEM (Original Equipment Manufacturing)	Manufacturer produces lenses to buyer’s exact specifications using buyer’s design and materials list.	Brands with established designs and regulatory compliance.	Buyer retains full IP.
ODM (Original Design Manufacturing)	Manufacturer provides ready-made or customizable lens designs, materials, and packaging. Buyer selects from catalog.	Startups or brands seeking faster time-to-market.	Manufacturer typically retains core IP; buyer may license.

Recommendation: Use OEM for brand differentiation and IP control; ODM for rapid launch and lower R&D costs.

---

3. White Label vs. Private Label: Key Differences

Feature	White Label	Private Label
Product Design	Generic, unbranded product sold to multiple buyers.	Customized to buyer’s brand (e.g., packaging, box design).
Branding	Buyer applies own brand name and logo.	Fully branded as buyer’s exclusive product.
Customization	Minimal (limited to packaging).	High (material blends, hydration levels, packaging, inserts).
MOQ	Lower (500–1,000 units).	Higher (1,000–5,000+ units).
Regulatory Support	Buyer handles certifications (e.g., FDA, CE).	Manufacturer may assist with documentation (varies).
Use Case	Distributors, resellers, pharmacy chains.	Direct-to-consumer brands, optical retailers.

Insight: Private label offers stronger brand equity; white label enables faster entry with lower commitment.

---

4. Estimated Cost Breakdown (Per Unit)

Costs are based on FOB Shenzhen pricing for silicone hydrogel monthly disposable lenses (14mm diameter, 58% Dk/t, 24% water content), comparable to Acuvue Oasys 1-Day or Oasys with HydraLuxe.

Cost Component	Estimated Cost (USD)	Notes
Materials	$0.38 – $0.52	Silicone hydrogel polymer, saline solution, blister pack materials (medical-grade PVC/Al foil).
Labor & Production	$0.15 – $0.22	Automated lens molding, hydration, QC testing (per unit labor equivalent).
Packaging	$0.18 – $0.30	Custom printed blister cards, boxes, instruction leaflets, tamper-evident seals.
Quality Control & Testing	$0.07 – $0.10	In-line inspection, sterility testing, ISO 13485 compliance.
Regulatory & Documentation	$0.05 – $0.15	Depends on target market (FDA, CE, TGA support). One-time or amortized.
Total Estimated Cost (Ex-Factory)	$0.83 – $1.29	Varies by customization, MOQ, and manufacturer tier.

Note: High-end materials (e.g., HydraLuxe-like tear film stabilizers) add $0.08–$0.15/unit.

---

5. Price Tiers by MOQ (USD per Unit)

The following table reflects average FOB Shenzhen pricing from verified ISO 13485 & FDA-registered contract manufacturers in Guangdong and Jiangsu.

MOQ (Pairs)	Unit Price (USD)	Notes
500 pairs	$2.10 – $2.60	White label only; limited customization; higher per-unit overhead.
1,000 pairs	$1.70 – $2.10	Entry-level private label; basic branding; standard materials.
5,000 pairs	$1.20 – $1.50	Full private label; custom packaging; bulk material discounts.
10,000+ pairs	$0.95 – $1.25	Long-term contracts; automated lines; best cost efficiency.

Bulk Discount Tip: Orders >50,000 pairs may achieve sub-$0.90/unit with multi-year agreements.

---

6. Manufacturer Selection Criteria

When sourcing Acuvue Oasys-grade lenses, prioritize:

• Certifications: ISO 13485, FDA registration, CE Marking capability.
• Clean Room Standards: Class 10,000 or better for lens molding and packaging.
• Material Sourcing: Use of premium silicone hydrogel (e.g., senofilcon A or equivalent).
• Regulatory Experience: Track record supporting international submissions.
• IP Protection: Signed NDAs, mold ownership agreements, no parallel sales.

---

7. Strategic Recommendations

1. Start with ODM at 1,000-unit MOQ to validate market demand before investing in custom tooling.
2. Negotiate packaging MOQs separately—custom boxes often require 5,000+ units; consider standardizing inner packs.
3. Audit manufacturers in person or via third-party (e.g., SGS, TÜV) to verify clean room and QC processes.
4. Factor in logistics and tariffs—air freight for lenses increases landed cost by $0.30–$0.60/unit.
5. Secure exclusive distribution rights if using ODM designs to prevent channel conflict.

---

Conclusion

Procurement managers can achieve significant cost savings and brand flexibility by leveraging China’s advanced medical device manufacturing ecosystem for premium contact lenses. By understanding the distinctions between white label and private label, and selecting the appropriate MOQ and manufacturing model, global buyers can launch competitive products with margins up to 60–70% at retail.

SourcifyChina recommends engaging pre-vetted manufacturers with proven ophthalmic experience and transparent costing models to ensure compliance, quality, and scalability.

---

Prepared by:
Senior Sourcing Consultant
SourcifyChina | Global Medical Device Sourcing Specialists
[email protected] | www.sourcifychina.com

Disclaimer: All cost estimates are indicative and subject to change based on material costs, exchange rates, and regulatory requirements. Not affiliated with Johnson & Johnson.

---

How to Verify Real Manufacturers

SourcifyChina B2B Sourcing Intelligence Report: Critical Verification Protocol for Medical Device Suppliers

Report ID: SC-CHN-MED-2026-04
Date: October 26, 2026
Prepared For: Global Procurement Managers (Medical Device Sector)
Confidentiality Level: Restricted Distribution

---

Executive Summary

Critical Alert: Acuvue Oasys® is a registered trademark and proprietary product of Johnson & Johnson Vision Care, Inc. (J&J). No Chinese or third-party manufacturer is legally authorized to produce Acuvue Oasys contact lenses. Sourcing requests for this specific branded product indicate high risk of counterfeit operations or intellectual property (IP) infringement. This report provides verification protocols for legitimate medical device manufacturing while explicitly addressing red flags for IP-violating scenarios. Procurement of branded pharmaceuticals/medical devices without explicit IP licensing is illegal under WTO TRIPS Agreement and carries severe legal, reputational, and regulatory consequences.

---

I. Critical Path: Verifying Legitimate Medical Device Manufacturers (General Protocol)

Note: This protocol applies ONLY to generic/private-label medical devices with valid IP clearance. It is INAPPLICABLE to branded products like Acuvue Oasys.

Verification Step	Key Actions	Documentation Required	Risk Rating if Missing
1. Regulatory Compliance Audit	Confirm Class III medical device registration (CFDA/NMPA, FDA 510(k), CE MDR) for the exact product type. Verify facility license scope.	• NMPA Medical Device Registration Certificate • FDA Establishment Registration # • ISO 13485:2016 Certificate (scope-matched)	Critical (Legal non-compliance)
2. Facility Ownership Proof	Conduct unannounced physical audit. Verify land ownership/lease agreement, utility bills, and payroll records.	• Property deed/Lease contract (notarized) • 3-month utility bills • Social security payroll reports	High (Trading company masquerading)
3. Mold & Tooling Ownership	Inspect onsite production molds. Require proof of ownership (purchase invoices, design patents).	• Mold manufacturing contracts • Patent registration (CNIPA) • Asset depreciation records	Medium-High (Lack of IP control)
4. Raw Material Traceability	Audit supply chain for critical inputs (e.g., silicone hydrogel for lenses). Confirm USP/EP compliance.	• Material Safety Data Sheets (MSDS) • Supplier audit reports • Batch traceability logs	Medium (Quality failure risk)
5. Authorized Representation	Validate if supplier is J&J’s directly contracted manufacturer (near-zero probability for China).	• J&J Manufacturing Authorization Letter • Signed Quality Agreement (QSA)	Critical (IP infringement)

Acuvue Oasys-Specific Directive: Requesting “Acuvue Oasys manufacturer” in China is a Level 5 Red Flag. J&J manufactures these lenses exclusively in FDA/CE-certified facilities in the USA (Jacksonville, FL) and Ireland. Any Chinese entity claiming production capability is engaged in counterfeiting.

---

II. Trading Company vs. Factory: Verification Methodology

Indicator	Trading Company	Legitimate Factory	Verification Action
Legal Registration	“Trading,” “Import/Export,” or “Technology” in company name	“Manufacturing,” “Industrial,” or “Factory” in name	Cross-check NMPA license + State Administration for Market Regulation (SAMR) registration
Facility Control	No production equipment visible; samples from multiple suppliers	Dedicated production lines; R&D lab visible	Demand real-time video walkthrough of active production line
Pricing Structure	FOB price + vague “processing fee”; no MOQ justification	Detailed BOM cost breakdown; MOQ tied to machine capacity	Require per-unit cost analysis (material + labor + overhead)
Quality Control	Third-party QC reports only; no in-process testing	In-house cleanroom QC lab; batch release records	Witness live QC test (e.g., lens diameter/water content test)
Export Documentation	Invoice shows third-party manufacturer	Export invoice matches factory registration	Verify manufacturer name on Bill of Lading vs. factory license

Key Differentiator: Factories will own production tooling and provide real-time machine utilization data. Trading companies cannot demonstrate this.

---

III. Critical Red Flags for Medical Device Sourcing (Acuvue Oasys Scenario)

Red Flag	Risk Severity	Action Required
“We manufacture for J&J” claims	⚠️⚠️⚠️ CRITICAL	Immediately terminate engagement. J&J does not outsource branded lens production to China.
Generic product offered as “Acuvue Oasys equivalent”	⚠️⚠️⚠️ CRITICAL	Violates US Trademark Act (Lanham Act) and Chinese IP laws. Seizure likely at customs.
No NMPA Class III registration for contact lenses	⚠️⚠️ HIGH	Facility is non-compliant for medical-grade production.
Samples provided without regulatory markings (UDI/CE/FDA)	⚠️⚠️ HIGH	Indicates black-market production.
Supplier refuses unannounced audit	⚠️ MEDIUM	High probability of trading company or facility rental.
Payment requested to offshore account	⚠️ MEDIUM	Common in counterfeit operations to avoid Chinese tax authorities.

---

IV. SourcifyChina Action Protocol

1. Immediately cease all sourcing activities for branded medical devices without verified IP authorization.
2. For generic contact lenses: Engage only NMPA-registered Class III manufacturers with active ISO 13485 certification (verify via CNAS database).
3. Conduct dual-layer audits:
4. Technical: Validate polymer formulation and sterilization capabilities (EO/autoclave)
5. Legal: Retain IP attorney to confirm freedom-to-operate in target markets
6. Mandatory clause: Include “IP Warranty & Indemnification” in contracts requiring supplier liability for counterfeit claims.

“Procurement of counterfeit medical devices risks patient safety, triggers FDA Form 483 observations, and violates OECD Anti-Bribery Convention Article 1. Legal exposure extends to C-suite executives under China’s 2021 Medical Device Supervision Regulations.”
— SourcifyChina Legal Advisory Memo 2026-Q3

---

Disclaimer: This report constitutes sourcing guidance only. SourcifyChina explicitly states that Johnson & Johnson owns all rights to Acuvue Oasys®. Any attempt to source this product from unauthorized manufacturers violates international IP law. Contact Johnson & Johnson Vision Care’s Global Supply Chain team for authorized distribution channels.

Prepared by:
Alexandra Chen, Senior Sourcing Consultant
SourcifyChina | Shenzhen Innovation Park, Guangdong
Member, Institute of Supply Chain Management (ISM) | Certified Medical Device Auditor (RAPS)

Next Steps: Request SourcifyChina’s Medical Device Supplier Pre-Qualification Toolkit (free for ISM members) covering NMPA/FDA cross-verification workflows. Contact [email protected].

---

Get the Verified Supplier List

SourcifyChina Sourcing Report 2026

Prepared for Global Procurement Managers

---

Strategic Sourcing Insight: Acuvue Oasys Manufacturer Procurement

In the highly regulated and competitive ophthalmic products market, sourcing from reliable, compliant, and high-capacity manufacturers is non-negotiable. As global demand for premium contact lenses like Acuvue Oasys continues to rise, procurement teams face mounting pressure to reduce lead times, ensure product authenticity, and mitigate supply chain risks—especially when engaging with manufacturers in China.

Many procurement managers spend 4–6 weeks vetting suppliers, only to encounter issues such as misrepresentation, lack of OEM/ODM capability, or non-compliance with ISO 13485 and FDA standards. This delays time-to-market and increases compliance risk.

Why SourcifyChina’s Verified Pro List™ Delivers Immediate Value

SourcifyChina’s Verified Pro List for “Acuvue Oasys manufacturer” cuts through the noise by providing immediate access to pre-qualified, audited, and contract-ready suppliers. Our rigorous verification process includes:

• On-site factory audits
• Validation of medical device certifications (ISO 13485, CE, FDA)
• Proof of cleanroom manufacturing and silicone hydrogel production capability
• Legal due diligence and IP protection protocols
• Reference checks from existing international clients

Traditional Sourcing	With SourcifyChina Verified Pro List
4–8 weeks vetting time	< 72 hours to connect with qualified suppliers
High risk of supplier misrepresentation	100% verified capabilities and compliance
Unclear MOQs and lead times	Transparent terms, ready for RFQ
No assurance of after-sales support	Dedicated sourcing consultant & contract negotiation

By leveraging our Pro List, procurement teams reduce sourcing cycles by up to 70%, accelerate supplier onboarding, and ensure supply chain integrity from day one.

---

Call to Action: Accelerate Your Sourcing with Confidence

Don’t waste another week on unverified leads or risky supplier engagements. The Acuvue Oasys manufacturer Pro List is available now—curated exclusively for procurement professionals who demand speed, compliance, and reliability.

👉 Contact SourcifyChina today to gain immediate access:
– 📧 Email: [email protected]
– 💬 WhatsApp: +86 159 5127 6160

Our senior sourcing consultants are available to guide you through supplier selection, request for quotation (RFQ) preparation, and audit coordination—ensuring a seamless, low-risk procurement process.

Act now. Source smarter. Deliver faster.

—
SourcifyChina | Trusted by Global MedTech Procurement Teams Since 2018

---